Novateor Research Laboratories Ltd
₹ 32.8
0.61%
12 May
- close price
About
Incorporated in 2011, Novateor Research Laboratories Ltd is in the business of Oral Care and Personal Care products.[1]
Key Points
- Market Cap ₹ 19.9 Cr.
- Current Price ₹ 32.8
- High / Low ₹ 54.6 / 20.1
- Stock P/E 199
- Book Value ₹ 19.0
- Dividend Yield 0.00 %
- ROCE 1.67 %
- ROE 0.91 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 0.72% over last 3 years.
- Company has high debtors of 269 days.
- Promoter holding has decreased over last 3 years: -10.1%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.02 | 0.10 | 0.14 | 0.09 | 0.41 | 0.39 | 0.19 | 0.74 | 1.26 | 1.21 | 2.78 | 3.83 | |
| 0.02 | 0.11 | 0.08 | 0.04 | 0.13 | 0.53 | 0.52 | 0.92 | 1.60 | 1.54 | 2.92 | 3.93 | |
| Operating Profit | 0.00 | -0.01 | 0.06 | 0.05 | 0.28 | -0.14 | -0.33 | -0.18 | -0.34 | -0.33 | -0.14 | -0.10 |
| OPM % | 0.00% | -10.00% | 42.86% | 55.56% | 68.29% | -35.90% | -173.68% | -24.32% | -26.98% | -27.27% | -5.04% | -2.61% |
| 0.00 | 0.01 | 0.02 | 0.03 | 0.11 | 0.27 | 0.44 | 0.01 | 0.49 | 0.49 | 0.48 | 0.49 | |
| Interest | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.02 | 0.03 | 0.07 | 0.09 |
| Depreciation | 0.00 | 0.00 | 0.07 | 0.07 | 0.10 | 0.10 | 0.10 | 0.09 | 0.09 | 0.08 | 0.16 | 0.19 |
| Profit before tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 0.02 | 0.01 | -0.26 | 0.04 | 0.05 | 0.11 | 0.11 |
| Tax % | 24.14% | 150.00% | 0.00% | -11.54% | 0.00% | 40.00% | 27.27% | 18.18% | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | -0.01 | 0.01 | -0.23 | 0.04 | 0.03 | 0.08 | 0.10 | |
| EPS in Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.74 | -0.02 | 0.02 | -0.48 | 0.08 | 0.06 | 0.17 | 0.17 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 44% |
| 5 Years: | 82% |
| 3 Years: | 45% |
| TTM: | 38% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 58% |
| 3 Years: | 36% |
| TTM: | 25% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 35% |
| 3 Years: | 23% |
| 1 Year: | -43% |
| Return on Equity | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 1% |
| 3 Years: | 1% |
| Last Year: | 1% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 0.05 | 0.05 | 2.96 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 6.05 |
| Reserves | 0.88 | 0.88 | 0.88 | 0.88 | 1.11 | 3.73 | 3.74 | 3.01 | 3.04 | 3.93 | 5.71 | 5.45 |
| 0.75 | 0.76 | 0.87 | 0.82 | 0.01 | 0.00 | 0.24 | 0.24 | 0.84 | 1.11 | 0.91 | 1.02 | |
| 0.11 | 0.15 | 0.10 | 0.09 | 0.24 | 0.23 | 0.17 | 0.06 | 0.24 | 0.59 | 1.16 | 1.74 | |
| Total Liabilities | 1.79 | 1.84 | 1.90 | 1.84 | 4.32 | 8.79 | 8.98 | 8.14 | 8.95 | 10.46 | 12.61 | 14.26 |
| 1.59 | 1.64 | 1.66 | 1.59 | 3.55 | 3.45 | 3.36 | 1.94 | 1.78 | 2.43 | 3.41 | 3.24 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.44 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| 0.19 | 0.19 | 0.23 | 0.24 | 0.76 | 5.33 | 5.61 | 6.19 | 6.73 | 7.58 | 9.19 | 11.01 | |
| Total Assets | 1.79 | 1.84 | 1.90 | 1.84 | 4.32 | 8.79 | 8.98 | 8.14 | 8.95 | 10.46 | 12.61 | 14.26 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.01 | 0.05 | -0.07 | -3.42 | -0.27 | -0.97 | -0.97 | -0.98 | -1.03 | -0.18 | |
| 0.00 | 0.00 | -0.01 | 0.00 | -1.96 | -0.10 | -0.09 | 0.91 | 0.13 | -0.25 | -0.22 | -0.50 | |
| 0.00 | 0.00 | 0.00 | -0.03 | 2.03 | 4.18 | 0.32 | -0.13 | 0.58 | 1.10 | 1.43 | 0.89 | |
| Net Cash Flow | 0.00 | 0.00 | -0.01 | 0.02 | 0.00 | 0.67 | -0.04 | -0.18 | -0.26 | -0.13 | 0.18 | 0.20 |
| Free Cash Flow | 0.00 | 0.00 | 0.00 | 0.05 | -2.03 | -3.52 | -0.36 | -0.06 | -1.33 | -1.72 | -1.73 | -0.20 |
| CFO/OP | 0% | 17% | 100% | 0% | 2,443% | 82% | 539% | 285% | 297% | 736% | 180% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 365.00 | 219.00 | 182.50 | 243.33 | 133.54 | 233.97 | 384.21 | 212.09 | 202.78 | 337.85 | 271.78 | 268.75 |
| Inventory Days | 4,380.00 | 438.00 | 1,460.00 | 2,737.50 | 6,448.33 | 700.80 | 851.67 | 344.34 | 215.16 | 268.95 | 151.10 | 152.08 |
| Days Payable | 1,460.00 | 292.00 | 730.00 | 1,095.00 | 1,460.00 | 14.60 | 104.29 | 20.66 | 61.47 | 207.47 | 176.61 | 208.57 |
| Cash Conversion Cycle | 3,285.00 | 365.00 | 912.50 | 1,885.83 | 5,121.87 | 920.17 | 1,131.59 | 535.77 | 356.46 | 399.32 | 246.27 | 212.26 |
| Working Capital Days | 1,277.50 | 109.50 | 286.79 | 527.22 | 462.93 | 4,117.95 | 9,067.37 | 2,747.36 | 1,604.84 | 1,879.30 | 950.58 | 770.98 |
| ROCE % | 0.00% | 0.00% | 0.57% | 0.56% | 9.95% | 0.47% | 0.12% | 2.49% | 0.71% | 0.86% | 1.69% | 1.67% |
Insights
In beta| Mar 2021 | Mar 2022 | Dec 2023 | Mar 2025 | |
|---|---|---|---|---|
| Authorised Share Capital INR |
|
|||
| Promoter Shareholding Percentage (Pre-Preferential) % |
||||
| Public Shareholding Percentage (Pre-Preferential) % |
||||
| Number of Convertible Equity Warrants to be Issued Warrants |
||||
| Warrant Exercise Period Months |
||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Outcome for Approval And Adoption Of Audited Financial Results For The Half Year And Year Ended On March 31, 2026
30 May - Board approved audited standalone results for half/year ended 31 Mar 2026; auditor issued qualified opinion.
-
Board Meeting Intimation for Adoption Of Audited Financial Results For The Half Year And Year Ended On March 31, 2026
26 May - Board meets May 30, 2026 to approve audited FY26 and half-year results; trading window closed from April 1.
-
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
30 Apr - Novateor says it is not a Large Corporate under SEBI; FY2025-26 incremental borrowing was 0.7 Cr.
-
Launch Of New Product- Smiloshine Herbafresh Toothpaste
30 Apr - Launched SmiloShine Herbafresh Toothpaste on 30 Apr 2026 in 6g and 100g variants for domestic and international markets.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Apr - RTA issued Regulation 74(5) certificate for quarter ended 31 March 2026.
Business Overview:[1]
a) NRLL develops FDA-approved personal care products for clinical and commercial purposes.
b) It’s current Teeth Whitening products
are sold under the brand name Smile Shine
c) The company manufactures 3 different variants of Teeth Whitening Strips, Teeth White
Toothpaste and brush, Kids Toothpaste and
tongue cleaner, Teeth Whitening Gel, Power
Brush.
d) It intends to expand its business in cosmetics, various health care pharma products in the near future
e) The company’s customer base consists of Dentists as well as Cosmetic Parlors